Ruhr-University Bochum Researchers Report Research in Cutaneous T-Cell Lymphoma (Use of Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma: A Retrospective Case Collection).

Researchers from Ruhr-University Bochum have conducted a retrospective case collection study on the use of pegylated interferon alpha-2a (PEG-IFNa) in the treatment of cutaneous T-cell lymphoma (CTCL). CTCL is a rare and largely incurable type of lymphoma with limited treatment options. The study found that PEG-IFNa, especially when combined with skin-directed therapies, was effective in treating CTCL. Approximately 36% of patients achieved complete remission, 36% achieved partial remission, and 29% had stable disease. Adverse events were reported in 18% of patients, leading to discontinuation of therapy in 2 patients. The most common concomitant therapies were oral PUVA phototherapy and local radiotherapy. This research provides valuable insights into the efficacy and adverse events associated with PEG-IFNa therapy for CTCL. [Extracted from the article]